TheJakartaPost
Please Update your browser
Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.
Remdesivir has 'little or no effect' on Covid-19 mortality: WHO study
Remdesivir, which was part of the experimental cocktail given to US President Donald Trump when he caught the new coronavirus last month, was one of several reviewed in a large study of more than 11,000 people across 30 countries.
Change Size
An ampule of Gilead Sciences COVID-19 antiviral remdesivir is pictured during a news conference at the University Hospital Eppendorf (UKE) in Hamburg, Germany, April 8, as the spread of COVID-19 continues. (Reuters/Ulrich Perrey)
T
he antiviral drug remdesivir, considered one of the most promising COVID-19 treatments, turns out to do little to prevent deaths from the disease, according to a WHO-backed study.
Remdesivir, which was part of the experimental cocktail given to US President Donald Trump when he caught the new coronavirus last month, was one of several reviewed in a large study of more than 11,000 people across 30 countries.
The drug "appeared to have little or no effect on hospitalized COVID-19, as indicated by overall mortality, initiation of ventilation and duration of hospital stay," said the study posted online late Thursday.
The data, which has yet to be peer-reviewed or published in a scientific journal, seems to contradict at least two major US studies that have shown that remdesivir can reduce the duration of hospital stays for COVID-19 patients.
Washington authorized the emergency use of the medicine, made by US pharmaceutical company Gilead Sciences and originally intended as a treatment for Ebola - on May 1, followed by a range of other countries and the European Union.
